GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome – Posters Presented at American Epilepsy Society Annual Meeting – – New data includes...
GW Pharmaceuticals plc Announces Epidiolex(R) (cannabidiol) Data Presentations and Educational Programs at the American Society of Epilepsy Annual Meeting – Presentations include clinical results from Phase 3 programs in...
Wissington glasshouse to grow plants for epilepsy medicine Wissington, Norfolk – 25 October 2016 British Sugar, the leading UK beet sugar producer, announces today that its horticultural business is...
Goldman Sachs initiated coverage on GW Pharma (NASDAQ: GWPH) (AIM: GWP) on October 7th, with a “Buy” rating and a target of $189. The target was based on blend...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical...
Shares in GW Pharma (NASDAQ: GWPH) (AIM: GWP) shot up in trading today after Reuters posted an exclusive report that the company has hired investment bank Morgan Stanley in...
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) – – Positive FDA pre-NDA meeting...
With the completion of two Phase 3 clinical trials that showed its Epidiolex to be safe and effective, global interest in GW Pharma’s (NASDAQ: GWPH) pharmaceutical-grade cannabidiol (CBD) extracted from cannabis continues...
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved with high statistical significance (p=0.0135) showing that...
Most investors understand the importance of listening to quarterly conference calls, as companies will often reveal important information in either the prepared remarks or the Q&A that follows that isn’t conveyed...
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Dravet syndrome – – Initial LGS Phase...
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex LONDON, April 11, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical...
GW Pharma is trading near $74 following the issuance of a press release detailing the first of four late-stage clinical trials for its epilepsy drug, Epidiolex. The stock has...
GW Pharma (NASDAQ: GWPH) (LON: GWP) will soon announce the results from the first of four Phase 3 clinical trials for Epidiolex, its antiepileptic drug targeting seizure reduction for patients with...
GW Pharmaceuticals plc Reports First Quarter 2016 Financial Results and Operational Progress -Three Phase 3 Epidiolex clinical trials fully recruited above target sample size — on track for initial...
The Financial Times shared a great history of the ups and downs of GW Pharma (NASDAQ: GWPH), which will soon report the results of the first of four Phase...
GW Pharmaceuticals (NASDAQ: GWPH) reported its fiscal year-end results today and held a conference call after the market closed. One of the more interesting parts of the prepared remarks involved...
Pharmaceutical CBD (cannabidiol) Shows Promise for Children with Severe Epilepsy Significant seizure reduction in studies using CBD in combination with AEDs PHILADELPHIA, December 7, 2015 – Around the globe...
This next week will be a big one for GW Pharmaceuticals (NASDAQ: GWPH). In addition to presenting at the Piper Jaffray Healthcare Conference in NYC on Wednesday, it will...
GW Pharma (GWPH) plunged today before quickly recovering some of the losses following the release of an abstract of a study published to the American Epilepsy Society website in...
The stratospheric rise of medical marijuana as a possible recognized treatment for epilepsy, now underway, is an example of what can be achieved through the sharing of personal stories...
